Chimeric antigen receptor T-cell therapy: An emergency medicine focused review

Introduction: Several novel cancer therapies have been recently introduced, each with complications that differ from chemotherapy and radiation. Objective: This narrative review discusses complications associated with chimeric antigen receptor (CAR) T-cell therapy for emergency clinicians. Discussion: Novel immune-based cancer therapies including CAR T-cell therapy have improved the care of patients with malignancy, primarily lymphoma and leukemia. However, severe complications may arise, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxidty syndrome (ICANS). CRS is associated with excessive cytokine release that results in severe end organ injury. Patients present with fever and a range of symptoms based on the affected organs. Grading is determined by the need for cardiopulmonary intervention, while management focuses on resuscitation, evaluation for other concomitant conditions, and treatment with tocilizumab or steroids. ICANS is also associated with cytokine release, causing patients to present with a variety of neurologic features. A grading system is available for ICANS based on feature severity. Management is supportive with steroids. Other complications of CAR T-cell therapy include infusion reactions, hypogammaglobulinemia, tumor lysis syndrome, cytopenias, cardiac toxicity, and graft-versus-host disease. Conclusions: Knowledge of this novel cancer therapy class and the potential complications can improve the care of these patients in the emergency department setting. Published by Elsevier Inc.

Automated summary

CAR T-cell therapy represents a significant advancement in cancer treatment, but can lead to severe complications such as CRS and ICANS. Early recognition and management of these complications are crucial for patient outcomes.